Pengenalan
Halaman ini menyediakan analisis menyeluruh tentang sejarah dagangan orang dalam yang diketahui Patrick G Enright. Orang dalam ialah pegawai, pengarah atau pelabur penting dalam syarikat. Adalah haram bagi orang dalam untuk membuat perdagangan dalam syarikat mereka berdasarkan maklumat khusus bukan awam. Ini tidak bermakna haram bagi mereka untuk membuat sebarang perdagangan dalam syarikat mereka sendiri. Tetapi mereka mesti melaporkan semua perdagangan kepada SEC melalui Borang 4. Walaupun terdapat sekatan ini, penyelidikan akademik menunjukkan bahawa orang dalam - secara amnya - cenderung untuk mengatasi prestasi pasaran dalam syarikat mereka sendiri.
Purata Keuntungan Perdagangan
Purata keuntungan perdagangan ialah purata pulangan semua pembelian pasaran terbuka yang dibuat oleh orang dalam dalam tempoh tiga tahun terakhir. Untuk mengira ini, kami memeriksa setiap pembelian pasaran terbuka yang tidak dirancang oleh orang dalam, tidak termasuk semua dagangan yang ditandakan sebagai sebahagian daripada pelan dagangan 10b5-1. Kami kemudian mengira prestasi purata dagangan tersebut sepanjang 3, 6 dan 12 bulan, dengan purata setiap tempoh tersebut untuk menjana metrik prestasi akhir bagi setiap dagangan. Akhir sekali, kami puratakan semua metrik prestasi untuk mengira metrik prestasi untuk orang dalam. Senarai ini hanya termasuk orang dalam yang telah membuat sekurang-kurangnya tiga dagangan dalam dua tahun lepas.
Jika keuntungan berdagang orang dalam ini ialah "N/A", maka orang dalam sama ada tidak membuat sebarang pembelian pasaran terbuka dalam tempoh tiga tahun terakhir, atau dagangan yang mereka buat adalah terlalu baru untuk mengira metrik prestasi yang boleh dipercayai.
Kekerapan Kemas Kini: Harian
Syarikat dengan Kedudukan Orang Dalam yang Dilaporkan
Pemfailan SEC menunjukkan Patrick G Enright telah melaporkan pegangan atau perdagangan dalam syarikat berikut:
Sekuriti | Tajuk | Pegangan Terkini Dilaporkan |
---|---|---|
US:JAZZ / Jazz Pharmaceuticals plc | Director | 26,379 |
US:VERA / Vera Therapeutics, Inc. | Director | 3,596,593 |
Director | 1,710,589 | |
Director | 774,530 | |
US:LXEO / Lexeo Therapeutics, Inc. | 10% Owner | 2,567,100 |
US:APTX / Aptinyx Inc. | Director | 40,000 |
US:SRRA / Sierra Oncology Inc | 10% Owner | 8,015 |
US:INZY / Inozyme Pharma, Inc. | 10% Owner | 4,174,379 |
US:RPID / Rapid Micro Biosystems, Inc. | 10% Owner | 129,032 |
US:TALS / Talaris Therapeutics Inc | 10% Owner | 0 |
US:EAR / Eargo, Inc. | 10% Owner | 5,012 |
US:ETNB / 89bio, Inc. | 10% Owner | 891 |
Director | 0 | |
US:MTEM / Molecular Templates, Inc. | 10% Owner | 0 |
US:VERO / Venus Concept Inc. | 10% Owner | 7,332,238 |
US:AXNX / Axonics, Inc. | 10% Owner | 0 |
US:TCDA / Tricida Inc | 10% Owner | 0 |
US:COLL / Collegium Pharmaceutical, Inc. | 10% Owner | 45,620 |
US:KALA / KALA BIO, Inc. | 10% Owner | 0 |
US:CORT / Corcept Therapeutics Incorporated | Director | 114,675 |
US:ESPR / Esperion Therapeutics, Inc. | Director | 8,000 |
Bagaimana Mentafsir Carta
Carta berikut menunjukkan prestasi saham sekuriti selepas setiap dagangan pasaran terbuka dan tidak dirancang yang dibuat oleh Patrick G Enright. Perdagangan tidak dirancang ialah dagangan yang tidak dibuat sebagai sebahagian daripada pelan dagangan 10b5-1. Prestasi saham dicatatkan sebagai perubahan peratus kumulatif dalam harga saham. Sebagai contoh, jika perdagangan orang dalam dibuat pada 1 Januari 2019, carta akan menunjukkan perubahan peratusan harian sekuriti kepada hari ini. Jika harga saham naik dari $10 kepada $15 pada masa ini, perubahan peratus terkumpul dalam harga saham ialah 50%. Perubahan dalam harga daripada $10 kepada $20 ialah 100% dan perubahan dalam harga $10 hingga $5 ialah -50%.
Secara dasarnya, kami cuba untuk menentukan sejauh mana dagangan orang dalam berkait rapat dengan pulangan berlebihan (positif atau negatif) dalam harga saham untuk melihat sama ada orang dalam menetapkan masa dagangan mereka untuk mendapat keuntungan daripada maklumat orang dalam. Pertimbangkan situasi di mana orang dalam melakukan perkara ini. Dalam keadaan ini, kami menjangkakan sama ada (a) pulangan positif selepas pembelian, atau (b) pulangan negatif selepas jualan. Dalam kes (a), carta PEMBELIAN akan menunjukkan satu siri keluk condong ke atas, menunjukkan pulangan positif selepas setiap transaksi pembelian. Dalam kes (b), carta JUALAN akan menunjukkan satu siri keluk condong ke bawah, menunjukkan pulangan negatif selepas setiap transaksi jualan.
Walau bagaimanapun, ini sahaja tidak cukup untuk membuat kesimpulan. Jika, sebagai contoh, harga saham syarikat berada dalam pendakian bukan disebabkan kitaran selama bertahun-tahun, maka kami menjangkakan semua plot selepas pembelian akan condong ke atas. Begitu juga, kemerosotan bukan disebabkan kitaran selama bertahun-tahun akan mengakibatkan plot pasca perdagangan condong ke bawah. Kedua-dua carta ini tidak akan mencadangkan aktiviti perdagangan orang dalam.
Penunjuk terkuat ialah keadaan di mana harga saham adalah sangat kitaran, dan terdapat kedua-dua isyarat positif dalam carta PEMBELIAN dan plot negatif pada carta JUALAN. Situasi ini akan sangat menunjukkan orang dalam yang menentukan masa perdagangan untuk kelebihan kewangan mereka.
Pembelian Orang Dalam COLL / Collegium Pharmaceutical, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam COLL / Collegium Pharmaceutical, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam CORT / Corcept Therapeutics Incorporated - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam CORT / Corcept Therapeutics Incorporated - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ETNB / 89bio, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ETNB / 89bio, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam KALA / KALA BIO, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-07-25 | KALA | Longitude Capital Partners II, LLC | 215,000 | 15.0000 | 4,300 | 750.0000 | 3,225,000 | 51 | 1326.5 | 2,478,950 | 76.87 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam KALA / KALA BIO, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam LXEO / Lexeo Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-07 | LXEO | Longitude Capital Partners IV, LLC | 454,545 | 11.0000 | 454,545 | 11.0000 | 4,999,995 | 219 | 18.7600 | 3,527,269 | 70.55 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam LXEO / Lexeo Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam RPID / Rapid Micro Biosystems, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-07-19 | RPID | Longitude Capital Partners II, LLC | 150,000 | 20.0000 | 150,000 | 20.0000 | 3,000,000 | 17 | 24.8 | 720,000 | 24.00 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam RPID / Rapid Micro Biosystems, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam TRML / Tourmaline Bio, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-11 | TALS | Longitude Capital Partners III, LLC | 235,000 | 17.0000 | 235,000 | 17.0000 | 3,995,000 | 27 | 18.61 | 378,350 | 9.47 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam TRML / Tourmaline Bio, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam VERA / Vera Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam VERA / Vera Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam VERO / Venus Concept Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam VERO / Venus Concept Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam COLL / Collegium Pharmaceutical, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Sejarah Dagangan Orang Dalam
Jadual ini menunjukkan senarai lengkap dagangan orang dalam yang dibuat oleh Patrick G Enright seperti yang didedahkan kepada Suruhanjaya Bursa Sekuriti (SEC).
Tarikh Fail | Tarikh Tran | Borang | Simbol Saham | Sekuriti | Kod | Saham | Baki Saham | Peratus Ubah |
Saham harga |
Tran Nilai |
Baki Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
F - Taxes | -1,805 | 26,379 | -6.40 | 111.25 | -200,805 | 2,934,640 | |
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,507 | 28,184 | 14.21 | ||||
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 27,071 | 3,596,593 | 0.76 | 22.35 | 605,083 | 80,389,968 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 13,536 | 1,797,619 | 0.76 | 22.35 | 302,553 | 40,179,841 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 139,595 | 3,569,522 | 4.07 | 20.87 | 2,913,110 | 74,489,856 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 69,798 | 1,784,083 | 4.07 | 20.87 | 1,456,566 | 37,230,779 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
P - Purchase | 400,000 | 1,710,589 | 30.52 | 18.00 | 7,200,000 | 30,790,602 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
C - Conversion | 1,310,589 | 1,310,589 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
P - Purchase | 440,000 | 774,530 | 131.53 | 17.00 | 7,480,000 | 13,167,010 | |
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 334,530 | 334,530 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 1,003,592 | 1,727,404 | 138.65 | ||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 723,812 | 723,812 | |||||
2024-08-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,731 | 24,677 | 17.81 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
P - Purchase | 454,545 | 2,567,100 | 21.52 | 11.00 | 4,999,995 | 28,238,100 | |
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 319,126 | 2,112,555 | 17.79 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 1,793,429 | 1,793,429 | |||||
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,241 | 20,946 | -5.59 | 138.16 | -171,455 | 2,893,868 | |
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,075 | 22,187 | 16.09 | ||||
2023-02-08 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 1,714,285 | 1,714,285 | 7.00 | 11,999,995 | 11,999,995 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,000 | 0 | -100.00 | 152.88 | -305,751 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,069 | 19,112 | -9.77 | 149.90 | -310,149 | 2,864,942 | |
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,905 | 21,181 | -12.06 | 149.18 | -433,364 | 3,159,752 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,089 | 24,086 | -4.33 | 152.33 | -165,883 | 3,668,934 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,561 | 25,175 | 11.32 | ||||
2022-05-31 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2022-05-26 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9,925 | 9,925 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 840 | 8,015 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 252 | 2,404 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 588 | 5,611 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 7,175 | 7,175 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 2,152 | 2,152 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 5,023 | 5,023 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -1,964,771 | 0 | -100.00 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -175,000 | 0 | -100.00 | ||||
2022-04-21 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 1,355,000 | 4,174,379 | 48.06 | 3.69 | 4,999,950 | 15,403,459 | |
2022-04-05 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 333,333 | 3,429,927 | 10.76 | 15.00 | 4,999,995 | 51,448,905 | |
2022-02-02 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
P - Purchase | 175,000 | 175,000 | 27.00 | 4,725,000 | 4,725,000 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -1,477,125 | 0 | -100.00 | 13.20 | -19,498,050 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 487,451 | 1,964,771 | 33.00 | 13.20 | 6,434,353 | 25,934,977 | |
2021-08-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,000 | 2,000 | 137.75 | 275,500 | 275,500 | ||
2021-08-02 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,246 | 22,614 | 11.03 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 129,032 | 129,032 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Warrant |
C - Conversion | -645,160 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 500,000 | 500,000 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Warrant |
C - Conversion | -2,500,000 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series C1 Preferred Stock |
C - Conversion | -2,291,665 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Preferred Stock |
C - Conversion | -5,654,529 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Preferred Stock |
C - Conversion | -8,774,007 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
P - Purchase | 150,000 | 150,000 | 20.00 | 3,000,000 | 3,000,000 | ||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
C - Conversion | 3,344,038 | 3,407,952 | 5,232.09 | ||||
2021-07-14 | 3 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
63,914 | ||||||||
2021-06-01 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -2,187,504 | 0 | -100.00 | ||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 909,090 | 3,096,594 | 41.56 | 11.00 | 9,999,990 | 34,062,534 | |
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 2,187,504 | 2,187,504 | |||||
2021-05-17 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9,925 | 9,925 | |||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -406,338 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,271,027 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,308,410 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
P - Purchase | 235,000 | 3,220,775 | 7.87 | 17.00 | 3,995,000 | 54,753,175 | |
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
C - Conversion | 2,985,775 | 2,985,775 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | 5,012 | 5,012 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | X | -1,000,000 | 2,918,691 | -25.52 | |||
2021-01-05 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,149 | 8,149 | 2.22 | 18,123 | 18,123 | ||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 891 | 891 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2,080 | 2,080 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2,973 | 2,973 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | -850,000 | 1,750,877 | -32.68 | ||||
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,623 | 20,368 | -7.38 | 147.61 | -239,575 | 3,006,565 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,083 | 21,991 | -18.77 | 147.00 | -747,217 | 3,232,747 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3,223 | 27,074 | -10.64 | 145.81 | -469,946 | 3,947,665 |
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
M - Exercise | -9,929 | 0 | -100.00 | ||||
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | 9,929 | 30,297 | 48.75 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Series E Preferred Stock |
C - Conversion | -3,685,358 | 0 | -100.00 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
P - Purchase | 233,333 | 3,918,691 | 6.33 | 18.00 | 4,199,994 | 70,536,438 | |
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
C - Conversion | 3,685,358 | 3,685,358 | |||||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -15,398 | 0 | -100.00 | 17.39 | -267,771 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -11,432 | 0 | -100.00 | 14.60 | -166,907 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -7,500 | 0 | -100.00 | 1.71 | -12,825 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -17,500 | 0 | -100.00 | 16.24 | -284,200 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -19,755 | 0 | -100.00 | 19.10 | -377,320 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -52,421 | 0 | -100.00 | 28.21 | -1,478,796 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -65,849 | 0 | -100.00 | 34.36 | -2,262,572 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
D - Sale to Issuer | -7,840 | 0 | -100.00 | 34.50 | -270,480 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -91,697 | 0 | -100.00 | 34.50 | -3,163,546 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -70,561 | 0 | -100.00 | 34.50 | -2,434,354 | ||
2020-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,379 | 8,379 | 2.16 | 18,124 | 18,124 | ||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 91,697 | 91,697 | |||||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -6,113,134 | 0 | -100.00 | ||||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -1,049 | 0 | -100.00 | 10.75 | -11,273 | ||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -2,447 | 0 | -100.00 | 10.75 | -26,296 | ||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 6,765 | 6,765 | |||||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,705 | 20,368 | 15.31 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1,398,600 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -15,000,000 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 625,000 | 2,819,379 | 28.48 | 16.00 | 10,000,000 | 45,110,064 | |
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 187,154 | 2,194,379 | 9.32 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 2,007,225 | 2,007,225 | |||||
2020-07-14 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 109,090 | 2,600,877 | 4.38 | 27.50 | 2,999,975 | 71,524,118 | |
2020-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,436 | 5,436 | 2.68 | 14,552 | 14,552 | ||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,398 | 15,398 | |||||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
S - Sale | 7,840 | 78,401 | 11.11 | ||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 1,049 | 1,049 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 2,447 | 2,447 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 3,495 | 3,495 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | -1,000,000 | 3,199,035 | -23.81 | ||||
2020-05-22 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2020-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,573 | 8,573 | 1.36 | 11,625 | 11,625 | ||
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 16,213 | 70,561 | 29.83 | 11.06 | 179,345 | 780,532 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 8,787 | 54,348 | 19.29 | 11.50 | 101,050 | 625,002 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 100,000 | 6,113,134 | 1.66 | 11.40 | 1,139,650 | 69,668,332 | |
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -19,500 | 0 | -100.00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 1,477,320 | 1,477,320 | |||||
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 166,667 | 3,356,746 | 5.22 | 3.00 | 500,001 | 10,070,238 | |
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 95,000 | 95,000 | 3.00 | 285,000 | 285,000 | ||
2020-01-03 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,427 | 5,427 | 2.14 | 11,625 | 11,625 | ||
2019-12-05 |
|
4/A | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937,500 | 4,199,035 | 28.74 | 8.00 | 7,500,000 | 33,592,280 | |
2019-11-27 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937,000 | 4,198,535 | 28.73 | 8.00 | 7,496,000 | 33,588,280 | |
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Series A Preferred Stock |
C - Conversion | -11,916,667 | 0 | -100.00 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
C - Conversion | 1,916,787 | 2,491,787 | 333.35 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 575,000 | 575,000 | 16.00 | 9,200,000 | 9,200,000 | ||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,582 | 5,582 | 2.08 | 11,622 | 11,622 | ||
2019-09-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 12,500 | 45,561 | 37.81 | 22.34 | 279,216 | 1,017,710 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -726 | 17,663 | -3.95 | 135.65 | -98,481 | 2,395,967 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 4,805 | 4,805 | |||||
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,920 | 18,389 | 11.66 | ||||
2019-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,866 | 5,866 | 1.98 | 11,626 | 11,626 | ||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 11,432 | 11,432 | |||||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 6,442 | 33,061 | 24.20 | ||||
2019-05-17 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2019-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 4,793 | 4,793 | 2.42 | 11,623 | 11,623 | ||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -2,000,000 | 0 | -100.00 | ||||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
P - Purchase | 533,333 | 2,933,333 | 22.22 | 15.00 | 7,999,995 | 43,999,995 | |
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
C - Conversion | 2,400,000 | 2,400,000 | |||||
2018-09-25 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 365,000 | 3,261,535 | 12.60 | 5.50 | 2,007,500 | 17,938,442 | |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,415 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,415 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,300 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,000 | 16,469 | -5.72 | 169.69 | -169,694 | 2,794,690 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7,086 | 17,469 | -28.86 | 168.86 | -1,196,565 | 2,949,873 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2,044 | 24,555 | -7.68 | 167.96 | -343,305 | 4,124,199 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,300 | 26,599 | 14.16 | 135.44 | 446,952 | 3,602,569 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,415 | 23,299 | 17.17 | 138.08 | 471,543 | 3,217,126 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,415 | 19,884 | 20.74 | 143.66 | 490,599 | 2,856,535 |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,365 | 16,469 | -7.65 | 175.13 | -239,057 | 2,884,272 | |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,735 | 3,735 | |||||
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,495 | 17,834 | 9.15 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1,817,447 | 0 | -100.00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -9,677,419 | 0 | -100.00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
P - Purchase | 131,579 | 3,019,734 | 4.56 | 19.00 | 2,500,001 | 57,374,946 | |
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 456,644 | 2,888,155 | 18.78 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 2,431,511 | 2,431,511 | |||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series B Convertible Preferred Stock |
C - Conversion | -21,946,301 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -33,022,786 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -28,895,188 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 150,000 | 3,190,079 | 4.93 | 16.00 | 2,400,000 | 51,041,264 | |
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 795,553 | 3,040,079 | 35.44 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1,197,076 | 2,244,526 | 114.28 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1,047,450 | 1,047,450 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 7,500 | 7,500 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 3,750 | 26,619 | 16.40 | ||||
2018-02-26 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock |
P - Purchase | 15,593 | 22,869 | 214.31 | 32.00 | 498,976 | 731,808 | |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -4,500 | 0 | -100.00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-employee director stock option |
M - Exercise | X | -4,500 | 0 | -100.00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2,842 | 16,339 | -14.82 | 140.50 | -399,294 | 2,295,592 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,358 | 19,181 | -21.83 | 139.56 | -747,771 | 2,676,931 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -800 | 24,539 | -3.16 | 138.14 | -110,516 | 3,389,940 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4,500 | 25,339 | 21.59 | 81.76 | 367,920 | 2,071,717 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4,500 | 20,839 | 27.54 | 46.83 | 210,735 | 975,890 |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -19,650 | 45,620 | -30.11 | 17.34 | -340,731 | 791,051 | |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -980,350 | 2,276,222 | -30.10 | 17.34 | -16,999,269 | 39,469,689 | |
2017-11-21 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -352 | 1,365 | -20.50 | 133.19 | -46,883 | 181,804 |
2017-08-28 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -351 | 1,717 | -16.97 | 148.40 | -52,088 | 254,803 |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 2,068 | -0.14 | 144.13 | -432 | 298,062 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -659 | 2,071 | -24.14 | 142.36 | -93,815 | 294,828 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,365 | 2,730 | 100.00 | ||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -10,707,985 | 0 | -100.00 | ||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 215,000 | 2,270,946 | 10.46 | 15.00 | 3,225,000 | 34,064,190 | |
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2,055,946 | 2,055,946 | |||||
2017-05-30 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 17,500 | 17,500 | |||||
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,305 | 114,675 | -4.42 | 9.94 | -52,722 | 1,139,652 | |
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -264,650 | 5,721,372 | -4.42 | 9.94 | -2,630,515 | 56,868,149 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,483 | 139,630 | -3.78 | 10.24 | -56,131 | 1,429,420 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -273,537 | 6,966,372 | -3.78 | 10.24 | -2,800,636 | 71,325,896 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,895 | 145,113 | -3.90 | 10.01 | -59,002 | 1,452,422 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -294,105 | 7,239,909 | -3.90 | 10.01 | -2,943,668 | 72,463,525 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -412 | 151,008 | -0.27 | 11.13 | -4,585 | 1,680,583 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -20,568 | 7,534,014 | -0.27 | 11.13 | -228,905 | 83,847,549 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14,737 | 151,420 | -8.87 | 9.75 | -143,686 | 1,476,345 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -735,263 | 7,554,582 | -8.87 | 9.75 | -7,168,814 | 73,657,174 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -19,650 | 166,157 | -10.58 | 9.05 | -177,832 | 1,503,721 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -980,350 | 8,289,845 | -10.58 | 9.05 | -8,872,168 | 75,023,097 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -29,475 | 185,807 | -13.69 | 8.65 | -254,959 | 1,607,231 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,470,525 | 9,270,195 | -13.69 | 8.65 | -12,720,041 | 80,187,187 | |
2016-12-14 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | 204,210 | 204,210 | |||||
2016-12-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -677 | 1,365 | -33.15 | 101.80 | -68,919 | 138,957 |
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 7,276 | 7,276 | |||||
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -1,500,000 | 6,013,134 | -19.97 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -58,950 | 121,153 | -32.73 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -2,941,050 | 10,834,849 | -21.35 | ||||
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -290 | 180,103 | -0.16 | 9.39 | -2,722 | 1,690,609 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14,451 | 13,775,899 | -0.10 | 9.39 | -135,650 | 129,312,986 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -248 | 180,393 | -0.14 | 9.30 | -2,307 | 1,678,340 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -12,352 | 13,790,350 | -0.09 | 9.30 | -114,921 | 128,302,658 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -189 | 180,641 | -0.10 | 9.33 | -1,763 | 1,685,326 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -9,411 | 13,802,702 | -0.07 | 9.33 | -87,802 | 128,775,069 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -2,327 | 180,830 | -1.27 | 9.39 | -21,841 | 1,697,270 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -116,058 | 13,812,113 | -0.83 | 9.39 | -1,089,320 | 129,640,493 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,976 | 183,157 | -1.07 | 9.47 | -18,720 | 1,735,156 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -98,586 | 13,928,171 | -0.70 | 9.47 | -933,964 | 131,949,921 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -6,389 | 185,133 | -3.34 | 9.64 | -61,612 | 1,785,312 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -318,764 | 14,026,757 | -2.22 | 9.64 | -3,073,969 | 135,265,628 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -342 | 191,522 | -0.18 | 9.51 | -3,252 | 1,821,125 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -17,052 | 14,345,521 | -0.12 | 9.51 | -162,142 | 136,407,256 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,094 | 191,864 | -1.59 | 9.55 | -29,558 | 1,832,954 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -154,359 | 14,362,573 | -1.06 | 9.55 | -1,474,653 | 137,211,405 | |
2016-08-17 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -633 | 2,042 | -23.66 | 136.45 | -86,373 | 278,631 | |
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,365 | 2,675 | 104.20 | ||||
2016-07-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
2016-05-27 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 19,755 | 19,755 | |||||
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,440 | 7,513,134 | 0.61 | 14.15 | 642,817 | 106,284,550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33,064 | 7,467,694 | 0.44 | 13.50 | 446,318 | 100,803,414 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,440 | 7,513,134 | 0.61 | 14.15 | 642,817 | 106,284,550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33,064 | 7,467,694 | 0.44 | 13.50 | 446,318 | 100,803,414 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7 | 4,323 | -0.16 | 120.31 | -842 | 520,085 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,330 | -0.78 | 119.55 | -4,065 | 517,639 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -63 | 4,364 | -1.42 | 118.39 | -7,459 | 516,669 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -52 | 4,427 | -1.16 | 117.46 | -6,108 | 519,984 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,479 | -0.75 | 116.19 | -3,951 | 520,422 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 4,513 | -0.13 | 114.43 | -687 | 516,408 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -393 | 215,677 | -0.18 | 120.32 | -47,288 | 25,951,227 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,666 | 216,070 | -0.77 | 119.55 | -199,165 | 25,830,542 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,159 | 217,736 | -1.43 | 118.40 | -374,013 | 25,779,050 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,594 | 220,895 | -1.16 | 117.46 | -304,692 | 25,946,415 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,698 | 223,489 | -0.75 | 116.20 | -197,304 | 25,968,930 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 225,187 | -0.13 | 114.43 | -33,641 | 25,767,405 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 4,519 | -0.53 | 139.24 | -3,342 | 629,220 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 4,543 | -1.24 | 138.37 | -7,887 | 628,594 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -116 | 4,600 | -2.46 | 137.71 | -15,974 | 633,454 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,214 | 225,481 | -0.54 | 139.24 | -169,043 | 31,397,034 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,843 | 226,695 | -1.24 | 138.36 | -393,371 | 31,366,563 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,746 | 229,538 | -2.44 | 137.71 | -791,274 | 31,609,357 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -424 | 1,310 | -24.45 | 148.49 | -62,960 | 194,522 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,716 | -0.72 | 147.57 | -5,018 | 695,960 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 4,750 | -1.41 | 146.95 | -9,993 | 698,035 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -94 | 4,818 | -1.91 | 145.96 | -13,720 | 703,245 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,737 | 235,284 | -0.73 | 147.58 | -256,339 | 34,722,225 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,395 | 237,021 | -1.41 | 146.95 | -498,900 | 34,830,591 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,672 | 240,416 | -1.91 | 145.96 | -681,940 | 35,091,889 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -18 | 4,912 | -0.37 | 137.96 | -2,483 | 677,663 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -36 | 4,930 | -0.72 | 137.16 | -4,938 | 676,174 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -32 | 4,966 | -0.64 | 135.85 | -4,347 | 674,626 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -62 | 4,998 | -1.23 | 134.76 | -8,355 | 673,548 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5,060 | -0.67 | 133.95 | -4,554 | 677,766 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8 | 5,094 | -0.16 | 132.70 | -1,062 | 675,974 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 5,102 | -0.12 | 128.96 | -774 | 657,954 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -932 | 245,088 | -0.38 | 137.98 | -128,595 | 33,816,752 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,809 | 246,020 | -0.73 | 137.15 | -248,097 | 33,740,634 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,573 | 247,829 | -0.63 | 135.85 | -213,693 | 33,667,669 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,138 | 249,402 | -1.24 | 134.76 | -422,878 | 33,609,463 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,666 | 252,540 | -0.66 | 133.95 | -223,154 | 33,826,698 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -392 | 254,206 | -0.15 | 132.70 | -52,018 | 33,733,136 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 254,598 | -0.12 | 128.96 | -37,914 | 32,832,958 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 5,108 | -0.02 | 137.81 | -138 | 703,933 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5,109 | -0.66 | 136.60 | -4,645 | 697,910 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5,143 | -0.19 | 135.73 | -1,357 | 698,039 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 5,153 | -0.48 | 134.32 | -3,358 | 692,137 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -83 | 5,178 | -1.58 | 132.94 | -11,034 | 688,358 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 5,261 | -0.81 | 132.26 | -5,687 | 695,799 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -99 | 254,892 | -0.04 | 137.81 | -13,643 | 35,126,667 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,695 | 254,991 | -0.66 | 136.60 | -231,540 | 34,832,230 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 256,686 | -0.19 | 135.73 | -66,506 | 34,838,964 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,225 | 257,176 | -0.47 | 134.32 | -164,539 | 34,543,160 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,193 | 258,401 | -1.60 | 132.94 | -557,414 | 34,351,622 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,102 | 262,594 | -0.79 | 132.26 | -278,000 | 34,729,369 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -37 | 5,304 | -0.69 | 168.33 | -6,228 | 892,798 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21 | 5,341 | -0.39 | 167.32 | -3,514 | 893,639 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 5,362 | -0.45 | 166.36 | -3,993 | 892,013 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5,386 | -1.05 | 165.26 | -9,420 | 890,074 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5,443 | -1.04 | 164.50 | -9,377 | 895,390 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,857 | 264,696 | -0.70 | 168.34 | -312,602 | 44,558,210 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,081 | 266,553 | -0.40 | 167.33 | -180,882 | 44,601,967 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,169 | 267,634 | -0.43 | 166.36 | -194,472 | 44,522,843 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,846 | 268,803 | -1.05 | 165.27 | -470,347 | 44,423,970 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,851 | 271,649 | -1.04 | 164.51 | -469,018 | 44,688,977 | |
2015-08-31 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -425 | 1,734 | -19.69 | 167.87 | -71,345 | 291,087 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -21 | 5,500 | -0.38 | 183.75 | -3,859 | 1,010,625 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -23 | 5,521 | -0.41 | 182.69 | -4,202 | 1,008,631 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -148 | 5,544 | -2.60 | 181.71 | -26,893 | 1,007,400 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 5,692 | -0.07 | 180.05 | -720 | 1,024,845 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,069 | 274,500 | -0.39 | 183.77 | -196,450 | 50,444,865 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,177 | 275,569 | -0.43 | 182.68 | -215,014 | 50,340,945 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7,362 | 276,746 | -2.59 | 181.71 | -1,337,749 | 50,287,516 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 284,108 | -0.07 | 180.05 | -35,290 | 51,153,645 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4 | 2,159 | -0.18 | 183.36 | -733 | 395,874 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -797 | 2,163 | -26.93 | 179.98 | -143,444 | 389,297 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,310 | 2,960 | 79.39 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,248,600 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,873,530 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312,500 | 7,434,630 | 4.39 | 16.00 | 5,000,000 | 118,954,080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,248,600 | 7,122,130 | 83.87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,873,530 | 3,873,530 | |||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,248,600 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,873,530 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312,500 | 7,434,630 | 4.39 | 16.00 | 5,000,000 | 118,954,080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,248,600 | 7,122,130 | 83.87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,873,530 | 3,873,530 | |||||
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5,696 | -0.18 | 178.59 | -1,786 | 1,017,254 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 5,706 | -1.04 | 177.74 | -10,665 | 1,014,196 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -105 | 5,766 | -1.79 | 176.86 | -18,570 | 1,019,761 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -22 | 5,871 | -0.37 | 175.81 | -3,868 | 1,032,165 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -543 | 284,304 | -0.19 | 178.59 | -96,977 | 50,775,017 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,986 | 284,847 | -1.04 | 177.74 | -530,727 | 50,628,222 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,196 | 287,833 | -1.77 | 176.86 | -918,943 | 50,904,964 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,078 | 293,029 | -0.37 | 175.81 | -189,520 | 51,516,637 | |
2015-06-22 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -47 | 5,893 | -0.79 | 179.43 | -8,433 | 1,057,379 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -109 | 5,940 | -1.80 | 178.76 | -19,485 | 1,061,831 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -40 | 6,049 | -0.66 | 177.82 | -7,113 | 1,075,614 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,397 | 294,107 | -0.81 | 179.43 | -430,099 | 52,772,266 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,447 | 296,504 | -1.80 | 178.76 | -973,685 | 53,001,928 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,960 | 301,951 | -0.64 | 177.82 | -348,521 | 53,691,961 | |
2015-05-18 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 8,000 | 8,000 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -101,128 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -5,045,381 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -63,356 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -3,160,905 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -257,303 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -12,837,935 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 3,930 | 65,270 | 6.41 | 12.00 | 47,160 | 783,240 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 61,340 | 61,340 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 196,070 | 3,256,572 | 6.41 | 12.00 | 2,352,840 | 39,078,864 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 3,060,502 | 3,060,502 | |||||
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 6,089 | -0.98 | 176.63 | -10,598 | 1,075,517 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -137 | 6,149 | -2.18 | 175.98 | -24,109 | 1,082,073 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,022 | 303,911 | -0.98 | 176.64 | -533,800 | 53,682,201 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,781 | 306,933 | -2.16 | 175.98 | -1,193,289 | 54,012,657 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 6,286 | -0.44 | 169.96 | -4,759 | 1,068,394 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6,314 | -1.94 | 169.23 | -21,154 | 1,068,545 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 6,439 | -0.66 | 168.31 | -7,237 | 1,083,760 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,402 | 313,714 | -0.44 | 169.97 | -238,301 | 53,322,753 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,275 | 315,116 | -1.95 | 169.24 | -1,061,958 | 53,329,097 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,127 | 321,391 | -0.66 | 168.32 | -358,008 | 54,095,280 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -16,833 | 0 | -100.00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -839,811 | 0 | -100.00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 16,833 | 194,958 | 9.45 | 4.05 | 68,174 | 789,580 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 839,811 | 14,516,932 | 6.14 | 4.05 | 3,401,235 | 58,793,575 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -1,130,709 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -554,348 | 13,677,121 | -3.90 | 5.65 | -3,132,066 | 77,275,734 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 1,130,709 | 14,231,469 | 8.63 | 2.77 | 3,132,064 | 39,421,169 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -9,750 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -486,443 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -634,516 | 1,130,709 | -35.95 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4,617 | 178,125 | -2.53 | 5.85 | -27,009 | 1,042,031 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 9,750 | 182,742 | 5.64 | 2.77 | 27,008 | 506,195 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -230,333 | 13,100,760 | -1.73 | 5.85 | -1,347,448 | 76,639,446 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 486,443 | 13,331,093 | 3.79 | 2.77 | 1,347,447 | 36,927,128 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -300,447 | 12,844,650 | -2.29 | 5.85 | -1,757,615 | 75,141,202 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 634,516 | 13,145,097 | 5.07 | 2.77 | 1,757,609 | 36,411,919 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -123 | 18,361 | -0.67 | 116.05 | -14,275 | 2,130,849 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -44 | 18,484 | -0.24 | 114.15 | -5,022 | 2,109,862 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3,907 | 18,528 | -17.41 | 113.92 | -445,080 | 2,110,682 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -67 | 22,435 | -0.30 | 111.06 | -7,441 | 2,491,618 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -5,684 | 22,502 | -20.17 | 110.01 | -625,279 | 2,475,375 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -6,077 | 916,035 | -0.66 | 116.05 | -705,254 | 106,308,610 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,156 | 922,112 | -0.23 | 114.15 | -246,097 | 105,254,751 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -194,988 | 924,268 | -17.42 | 113.92 | -22,212,701 | 105,291,039 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3,353 | 1,119,256 | -0.30 | 111.06 | -372,381 | 124,303,452 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -283,601 | 1,122,609 | -20.17 | 110.01 | -31,198,067 | 123,494,736 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6,482 | -0.05 | 177.51 | -533 | 1,150,620 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -87 | 6,485 | -1.32 | 176.79 | -15,381 | 1,146,501 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 6,572 | -0.86 | 176.03 | -10,033 | 1,156,838 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 6,629 | -0.57 | 175.06 | -6,652 | 1,160,498 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -12 | 6,667 | -0.18 | 172.60 | -2,071 | 1,150,713 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 323,518 | -0.06 | 177.51 | -34,969 | 57,427,680 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,302 | 323,715 | -1.31 | 176.79 | -760,560 | 57,230,319 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,854 | 328,017 | -0.86 | 176.02 | -502,374 | 57,738,996 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,862 | 330,871 | -0.56 | 175.06 | -325,969 | 57,923,535 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -588 | 332,733 | -0.18 | 172.60 | -101,488 | 57,429,150 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6,679 | -0.04 | 168.13 | -504 | 1,122,940 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 6,682 | -1.01 | 167.51 | -11,391 | 1,119,298 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6,750 | -1.82 | 166.45 | -20,807 | 1,123,568 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 333,321 | -0.06 | 168.14 | -33,123 | 56,042,960 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,382 | 333,518 | -1.00 | 167.51 | -566,507 | 55,866,400 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,225 | 336,900 | -1.81 | 166.46 | -1,036,187 | 56,078,925 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -9 | 6,875 | -0.13 | 161.54 | -1,454 | 1,110,588 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -88 | 6,884 | -1.26 | 160.75 | -14,146 | 1,106,600 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -100 | 6,972 | -1.41 | 159.68 | -15,968 | 1,113,262 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -495 | 343,125 | -0.14 | 161.57 | -79,975 | 55,437,368 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,348 | 343,620 | -1.25 | 160.75 | -698,938 | 55,236,709 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,960 | 347,968 | -1.41 | 159.68 | -792,002 | 55,562,765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 1,650 | -15.38 | 172.53 | -51,759 | 284,674 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -650 | 1,950 | -25.00 | 171.67 | -111,588 | 334,765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,393 | 2,600 | -34.89 | 170.32 | -237,256 | 442,832 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5 | 7,072 | -0.07 | 177.10 | -886 | 1,252,451 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 7,077 | -0.14 | 174.97 | -1,750 | 1,238,263 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7,087 | -0.67 | 173.73 | -8,339 | 1,231,216 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 7,135 | -0.83 | 173.03 | -10,382 | 1,234,553 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 7,195 | -0.35 | 171.65 | -4,291 | 1,235,033 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7,220 | -0.66 | 170.96 | -8,206 | 1,234,337 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -295 | 352,928 | -0.08 | 177.10 | -52,244 | 62,503,549 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 353,223 | -0.14 | 174.97 | -85,735 | 61,803,428 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,403 | 353,713 | -0.67 | 173.73 | -417,466 | 61,449,569 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,007 | 356,116 | -0.84 | 173.02 | -520,280 | 61,616,259 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,208 | 359,123 | -0.34 | 171.65 | -207,349 | 61,642,314 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,401 | 360,331 | -0.66 | 170.97 | -410,495 | 61,605,142 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -8 | 28,186 | -0.03 | 32.13 | -257 | 905,653 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -92 | 28,194 | -0.33 | 31.57 | -2,904 | 889,989 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -412 | 1,406,210 | -0.03 | 32.14 | -13,241 | 45,192,355 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4,592 | 1,406,622 | -0.33 | 31.56 | -144,944 | 44,399,179 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,722 | 28,286 | -8.78 | 33.79 | -91,975 | 955,773 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,728 | 31,008 | -8.09 | 32.93 | -89,844 | 1,021,214 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4,021 | 33,736 | -10.65 | 32.01 | -128,718 | 1,079,940 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -135,816 | 1,411,214 | -8.78 | 33.79 | -4,589,182 | 47,684,498 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -136,148 | 1,547,030 | -8.09 | 32.93 | -4,483,885 | 50,949,731 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -200,591 | 1,683,178 | -10.65 | 32.01 | -6,421,219 | 53,881,053 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -46 | 7,268 | -0.63 | 171.71 | -7,899 | 1,247,971 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -151 | 7,314 | -2.02 | 170.90 | -25,805 | 1,249,934 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,258 | 362,732 | -0.62 | 171.71 | -387,716 | 62,283,841 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7,545 | 364,990 | -2.03 | 170.90 | -1,289,438 | 62,376,682 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -19 | 37,757 | -0.05 | 30.00 | -570 | 1,132,710 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -924 | 1,883,769 | -0.05 | 30.00 | -27,720 | 56,513,070 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -235 | 37,776 | -0.62 | 30.04 | -7,059 | 1,134,802 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -11,692 | 1,884,693 | -0.62 | 30.04 | -351,230 | 56,616,555 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 7,465 | -0.57 | 161.57 | -6,947 | 1,206,085 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -104 | 7,508 | -1.37 | 160.65 | -16,708 | 1,206,165 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49 | 7,612 | -0.64 | 159.47 | -7,814 | 1,213,914 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,157 | 372,535 | -0.58 | 161.57 | -348,516 | 60,192,082 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,197 | 374,692 | -1.37 | 160.65 | -834,911 | 60,195,169 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,450 | 379,889 | -0.64 | 159.48 | -390,738 | 60,586,559 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 7,661 | -0.49 | 163.88 | -6,227 | 1,255,464 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -159 | 7,699 | -2.02 | 162.71 | -25,871 | 1,252,690 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,909 | 382,339 | -0.50 | 163.89 | -312,865 | 62,661,386 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7,894 | 384,248 | -2.01 | 162.71 | -1,284,424 | 62,520,569 | |
2014-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,087 | 3,993 | -21.40 | 133.15 | -144,734 | 531,668 | |
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3,300 | 3,300 | |||||
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,650 | 5,080 | 48.10 | ||||
2014-05-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 5,000 | 5,000 | |||||
2014-05-12 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,699 | 172,992 | -0.97 | 4.07 | -6,918 | 704,389 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -84,744 | 12,510,581 | -0.67 | 4.07 | -345,061 | 50,940,584 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,214 | 174,691 | -1.81 | 4.12 | -13,256 | 720,513 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -160,343 | 12,595,325 | -1.26 | 4.12 | -661,335 | 51,949,418 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4,912 | 177,905 | -2.69 | 4.28 | -21,035 | 761,843 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -245,088 | 12,755,668 | -1.89 | 4.28 | -1,049,540 | 54,623,597 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -205 | 182,817 | -0.11 | 4.00 | -820 | 731,268 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -10,225 | 13,000,756 | -0.08 | 4.00 | -40,900 | 52,003,024 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,303 | 183,022 | -1.77 | 4.00 | -13,214 | 732,216 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -164,800 | 13,010,981 | -1.25 | 4.00 | -659,315 | 52,053,032 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,404 | 186,325 | -0.75 | 4.01 | -5,630 | 747,126 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -70,063 | 13,175,781 | -0.53 | 4.01 | -280,939 | 52,832,247 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,895 | 0 | -100.00 | 153.80 | -599,043 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,166 | 3,895 | -23.04 | 150.45 | -175,429 | 586,017 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,700 | 5,061 | -42.23 | 149.42 | -552,855 | 756,216 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,700 | 8,761 | -23.56 | 148.55 | -401,088 | 1,301,456 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 11,461 | -2.55 | 147.87 | -44,360 | 1,694,700 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -18,624 | 0 | -100.00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -929,243 | 0 | -100.00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8,731 | 7,858 | -52.63 | 150.50 | -1,314,016 | 1,182,629 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -435,588 | 392,142 | -52.62 | 150.50 | -65,555,994 | 59,017,371 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -559 | 16,589 | -3.26 | 159.03 | -88,897 | 2,638,127 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28,070 | 827,730 | -3.28 | 159.03 | -4,463,927 | 131,632,578 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -423 | 17,148 | -2.41 | 159.91 | -67,642 | 2,742,121 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -20,977 | 855,800 | -2.39 | 159.91 | -3,354,449 | 136,851,663 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -180 | 17,571 | -1.01 | 160.77 | -28,939 | 2,824,944 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8,866 | 876,777 | -1.00 | 160.76 | -1,425,330 | 140,953,827 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -787 | 17,751 | -4.25 | 161.93 | -127,442 | 2,874,492 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -39,241 | 885,643 | -4.24 | 161.93 | -6,354,448 | 143,415,625 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -71 | 18,538 | -0.38 | 162.94 | -11,569 | 3,020,574 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,645 | 924,884 | -0.39 | 162.94 | -593,906 | 150,698,102 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 18,609 | -0.01 | 164.50 | -164 | 3,061,180 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 928,529 | 0.00 | 164.50 | -4,606 | 152,743,020 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -14 | 18,610 | -0.08 | 165.94 | -2,323 | 3,088,143 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -686 | 928,557 | -0.07 | 165.94 | -113,835 | 154,084,749 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 18,624 | 18,624 | 4.00 | 74,496 | 74,496 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 929,243 | 929,243 | 4.00 | 3,716,972 | 3,716,972 | ||
2013-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,070 | 3,430 | -23.78 | 81.86 | -87,590 | 280,780 | |
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 4,500 | 4,500 | |||||
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,250 | 4,500 | 100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 21,471 | 21,471 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -33,753 | 0 | -100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,683,967 | 0 | -100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4,258 | 38,011 | 12.62 | 14.00 | 59,612 | 532,154 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 212,418 | 1,896,385 | 12.61 | 14.00 | 2,973,852 | 26,549,390 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 33,753 | 33,753 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1,683,967 | 1,683,967 | |||||
2013-05-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -15,720 | 15,422 | -50.48 | 58.28 | -916,162 | 898,794 | |
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -784,280 | 768,670 | -50.50 | 58.28 | -45,707,838 | 44,798,088 | |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -921 | 31,142 | -2.87 | 58.13 | -53,536 | 1,810,228 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -46,451 | 1,552,950 | -2.90 | 58.13 | -2,700,085 | 90,269,256 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 32,063 | -0.01 | 59.04 | -236 | 1,893,000 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -375 | 32,067 | -1.16 | 58.41 | -21,905 | 1,873,110 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 1,599,401 | -0.01 | 59.04 | -11,572 | 94,428,635 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -18,703 | 1,599,597 | -1.16 | 58.41 | -1,092,476 | 93,435,340 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -456 | 32,442 | -1.39 | 56.72 | -25,865 | 1,840,159 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -22,772 | 1,618,300 | -1.39 | 56.72 | -1,291,669 | 91,792,889 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -31 | 32,898 | -0.09 | 56.54 | -1,753 | 1,860,033 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,569 | 1,641,072 | -0.10 | 56.54 | -88,710 | 92,785,226 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -706 | 32,929 | -2.10 | 56.52 | -39,906 | 1,861,299 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -35,216 | 1,642,641 | -2.10 | 56.52 | -1,990,563 | 92,849,297 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -117 | 33,635 | -0.35 | 56.52 | -6,612 | 1,900,932 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,783 | 1,677,857 | -0.34 | 56.52 | -326,834 | 94,826,437 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -72 | 33,752 | -0.21 | 59.34 | -4,273 | 2,002,877 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,228 | 33,824 | -3.50 | 58.59 | -71,946 | 1,981,681 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3,667 | 1,683,640 | -0.22 | 59.34 | -217,607 | 99,910,565 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -61,683 | 1,687,307 | -3.53 | 58.59 | -3,613,884 | 98,855,943 |
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Option (right to buy) |
A - Award | 4,500 | 4,500 | |||||
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,250 | 2,250 | |||||
2012-06-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
P - Purchase | 856,644 | 856,644 | 0.12 | 107,080 | 107,080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
X - Other | -856,644 | 0 | -100.00 | 0.12 | -107,080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 856,644 | 13,433,573 | 6.81 | 2.96 | 2,535,666 | 39,763,376 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21,615 | 35,052 | -38.14 | 49.56 | -1,071,239 | 1,737,177 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,078,400 | 1,748,990 | -38.14 | 49.56 | -53,445,504 | 86,679,944 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49,985 | 0 | -100.00 | 49.56 | -2,477,257 | ||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 18,624 | 18,624 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 929,243 | 929,243 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
A - Award | 9,929 | 9,929 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 56,667 | 56,667 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,827,390 | 2,827,390 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 49,985 | 49,985 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -18,624 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -929,243 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
D - Sale to Issuer | -9,929 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -56,667 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -2,827,390 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -49,985 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12,500 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12,500 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -10,000 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -30,000 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -8,999 | 49,985 | -15.26 | 48.60 | -437,351 | 2,429,271 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12,500 | 58,984 | 26.89 | 34.99 | 437,375 | 2,063,850 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2,116 | 46,484 | -4.35 | 48.60 | -102,838 | 2,259,122 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12,500 | 48,600 | 34.63 | 8.23 | 102,875 | 399,978 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1,302 | 36,100 | -3.48 | 48.60 | -63,277 | 1,754,460 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10,000 | 37,402 | 36.49 | 6.33 | 63,300 | 236,755 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2,598 | 27,402 | -8.66 | 48.60 | -126,263 | 1,331,737 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 30,000 | 30,000 | 4.21 | 126,300 | 126,300 |